Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Teva Stock Upgraded: What You Need to Know

By Rich Smith - Jul 5, 2019 at 3:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is 3.9 times earnings cheap? Yes. But other valuation metrics tell a different story.

Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...

With shares down 85% over the last four years -- and down 60% over the last 12 months alone -- Teva Pharmaceutical Industries ( TEVA -1.35% ) is arguably one of the most hated stocks on the planet.

Earlier this month, my fellow contributor Sean Williams laid out a few of the reasons for investors' aversion to the drugmaker: "Teva has been buried by debt following its Actavis acquisition, is contending with generic-price weakness and litigation concerns as an opioid retailer, settled with the Justice Department over international bribery allegations, cut its outlook multiple times, had its lead drug hit by generic competitors, and eliminated its dividend."

Wow. That's quite a lot of reasons! And yet, just this morning, analysts at Argus Research found a few reasons to recommend Teva stock. Let's see what they have to say.

Tumbling dice read buy and sell

Image source: Getty Images.

Upgrading Teva

First and foremost, Argus really likes the valuation on Teva stock. As the analyst explains today in a note covered by, Teva has historically averaged a forward price-to-earnings ratio of 8.6 -- but currently sells for just 3.9 times forward earnings. (That's also a discount to the 6.7 times forward earnings valuation the market is placing on peer generic drug producers.)

Granted, there are reasons (see above) for Teva shares being cheap, and Argus doesn't discount the "numerous challenges" the company is facing and admits it could encounter "several more challenging quarters" before things start to improve. Yet even so, the analyst argues that Teva isn't as reliant upon Copaxone (its "lead drug") sales as it once was, that generics in general are becoming a more stable business, and that the company has made progress in reducing its costs, which should pay off in greater profits going forward.

Meanwhile, Argus believes that 3.9 times earnings is an "excessive discount" on Teva shares, and that they should sell for something closer to $12, instead of the less than $10 they cost today.

Accordingly, Argus believes now is a good time to buy Teva stock on the cheap.

More optimism on Teva

Williams also tends to agree with this assessment, adding that in recent years Teva has leveraged its "$2 billion or more in operating cash flow per year" -- supplemented with proceeds from the sale of noncore assets -- to reduce its debt load by "about $8 billion" over the last couple of years.

Williams also notes that Teva is operating in a volume-based, lower-margin business, where costs are key. In light of Argus' observation that costs are coming down, this should work in the company's favor, especially given that -- as Sean points out -- "the sheer vastness of its portfolio should give it significant longer-term pricing power." 

Caveats and provisos

I only wish this "pricing power" were a little more obvious in the numbers Teva is producing today.

Consider: Williams rightly notes that Teva has demonstrated an ability to generate in excess of $2 billion in annual cash flow over the last two years ($2.2 billion in 2017, and $2.4 billion in 2018, to be precise). However, once you subtract spending on capital investment, actual free cash flow at the company -- the cash available to spend on paying down debt -- was only $1.4 billion and $1.8 billion, respectively, in those two years.

Moreover, Q1 2019 results were significantly weaker, and enough so to depress Teva's trailing-12-month cash flow down closer to $1 billion than to $2 billion -- and with only $449 million in positive free cash flow.

At the same time, while it's true Teva has made progress in reducing its debt load, total long-term debt still stands at a weighty $26.3 billion, according to the latest data from S&P Global Market Intelligence. Even offset by $2 billion in cash on the balance sheet, this is enough debt to give the drugmaker a total enterprise value of $34.6 billion -- more than three times the $10.4 billion market capitalization upon which the stock's P/E is based.

Long story short, at a recent enterprise value-to-free-cash-flow ratio of 77, Teva isn't nearly as cheap as its 3.9 forward P/E ratio suggests. In fact, I think Teva stock still looks downright pricey -- and not yet worthy of Argus' buy rating.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$8.05 (-1.35%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.